Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Belapectin misses endpoints in NASH trial

Key clinical point: The galectin-3 inhibitor belapectin did not improve hepatic venous pressure gradient or secondary outcomes in a clinical trial.

Major finding: After 52 weeks of infusions, the change in hepatic venous pressure gradient did not significantly differ between the 2-mg/kg group (–0.28 mm Hg) and the placebo group (0.10 mm Hg) or between the 8-mg/kg group (–0.25 mm Hg) and the placebo group (P = .1 for both comparisons).

Study details: Randomized, double-blind, placebo-controlled study of 162 patients with NASH, cirrhosis, and portal hypertension.

Disclosures: Galectin Therapeutics provided funding. Dr. Chalasani disclosed grant support from Galectin Therapeutics and relevant consulting relationships with NuSirt, AbbVie, Afimmune (DS Biopharma), and several other pharmaceutical companies. Sixteen coinvestigators also disclosed relationships with pharmaceutical companies, of whom eight disclosed consulting relationships, received research funding, or were employed by Galectin.

Citation:

Chalasani N et al. Gastroenterology. 2019 Dec 5. doi: 10.1053/j.gastro.2019.11.296.